Protein and RNA Expression Patterns in Predicting Response to Treatment in Patients With Lung Cancer
Study Details
Study Description
Brief Summary
RATIONALE: Studying samples of tumor tissue and blood in the laboratory from patients with cancer may help doctors learn more about changes that occur in genetic material (DNA and RNA) and may also identify protein expression patterns related to cancer. It may also help doctors predict how patients will respond to treatment.
PURPOSE: This research study evaluates changes in DNA, RNA, and proteins with the goal of predicting response to treatment in patients with lung cancer.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Detailed Description
OBJECTIVES:
-
To determine protein and/or RNA expression patterns capable of predicting tumor response to therapy in tumor tissue samples from patients with lung cancer or suspected of having lung cancer.
-
To characterize the genes and proteins found to be predictive of response in order to help elucidate the molecular biology underlying cancer chemosensitivity.
-
To evaluate DNA mutations found within the lung cancer sample which may be predictive of response or resistance to certain therapeutic agents.
OUTLINE: Patients undergo collection of tumor tissue by percutaneous fine needle aspiration, core biopsy, thoracentesis, or during any medically indicated procedure involving removal of lung cancer tissue. Tissue samples are analyzed by a variety of techniques, including DNA sequencing, RNA sequencing and expression levels, protein assessment [by immunohistochemistry, western blot, Matrix-assisted laser desorption/ionization time of flight mass spectrometry (MALDI-MS]). The goal of these studies is to identify of gene mutations, gene expression levels, and proteins predictive of treatment response. Blood samples are also collected to obtain normal DNA for analysis.
After completion of study, patients will be followed until their death.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Lung cancer Patients with a diagnosis of invasive lung cancer. |
Genetic: DNA/RNA sequencing and expression levels
Lung tumor tissue will be collected.
Genetic: Protein expression analysis
Lung tumor tissue will be collected.
Other Names:
Procedure: Lung tumor biopsy
Tissue will be collected by percutaneous fine needle aspiration, a percutaneous core biopsy, or during a medically indicated procedure during which lung tumor tissue will be removed
Procedure: Blood sample
Patients will be asked for a venous blood sample
|
Outcome Measures
Primary Outcome Measures
- DNA, RNA, and Protein expression patterns and mutational analysis [After lung tumor tissue and blood collection.]
DNA, RNA, and Protein expression patterns and mutation status in lung tumor tissue that are capable of predicting tumor response to therapy
Secondary Outcome Measures
- Characterization of genes and proteins predictive of response to therapy [After lung tumor tissue and blood collection]
Identify genes and proteins predictive of response to therapy and that can be used to identify novel mechanisms underlying lung cancer behavior
Eligibility Criteria
Criteria
Inclusion criteria
- Diagnosis of suspected lung cancer or lung cancer
Exclusion criteria
- Inability to undergo therapy
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Vanderbilt-Ingram Cancer Center | Nashville | Tennessee | United States | 37232-6838 |
Sponsors and Collaborators
- Vanderbilt-Ingram Cancer Center
- National Cancer Institute (NCI)
Investigators
- Study Chair: Christine Lovly, MD, PhD, Vanderbilt-Ingram Cancer Center
Study Documents (Full-Text)
None provided.More Information
Additional Information:
Publications
None provided.- VICC THO 0547
- P30CA068485
- VU-VICC-THO-0547
- P50CA090949